Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT02885324
Phase
PHASE2
Status
Terminated

Conditions

  • Anaplastic Astrocytoma
  • Glioblastoma Multiforme
  • High Grade Glioma
  • Malignant Brain Tumor

Eligibility Criteria

Sex
ALL
Age
2 Years - 21 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival

Key Dates

First listed
Aug 31, 2016
Start date
May 18, 2017
Status verified
Oct 2022
Primary completion
Aug 25, 2020
Completion
Aug 25, 2020

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib
    Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.

Primary Outcome Measure

Number of Participants With Disease Response [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Riley Hospital for Children at IU HealthIndianapolisIndiana46202-

Find similar trials in Indianapolis, IN

By research site
Riley Hospital for Children at IU Health· Indianapolis, IN

Related Studies